-
January 06, 2022Elpiscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, toda...
-
October 22, 2021Elpiscience to Present Two Programs at The Society for Immunotherapy of Cancer (“SITC”) 2021 Annual Meeting
Shanghai/Suzhou, China, and Maryland, US, October 22, 2021. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company focusing on discove...
-
October 15, 2021Elpiscience Announces CDE Clearance of IND Application for 欧洲杯买球网, Next-frontier Anti-angiogenesis Drug
Shanghai/Suzhou, China, October 15, 2021. Elpiscience Biopharma, a global clinical-stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today...
-
October 15, 2021Elpiscience Announces First Patient Dosed with 欧洲杯买球网APP in combination with Toripalimab in China
Shanghai/Suzhou, China, October 15, 2021. Elpiscience Biopharma, a global clinical-stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today...
-
September 10, 2021欧洲杯买球网 (CTX-009/ABL001) Clinical Data Presented at the 2021 AACR-NCI-EORTC International Conference
1. 欧洲杯买球网 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric orig...
-
September 10, 2021Elpiscience Announces FDA Approval of IND Application for 欧洲杯买球网 (anti-CD39 mAb)
Shanghai/Suzhou/Maryland, September 10, 2021. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company focusing on discovering and devel...
